期刊
HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA
卷 25, 期 4, 页码 813-+出版社
W B SAUNDERS CO-ELSEVIER INC
DOI: 10.1016/j.hoc.2011.04.006
关键词
Renal cell carcinoma; Clear cell carcinoma; Vascular endothelial growth factor; HIF; Bevacizumab; Sunitinib; Sorafenib; Pazopanib
Vascular endothelial growth factor (VEGF) is, to date, the key element in the pathogenesis of renal cell carcinoma (RCC). VEGF pathway activation is responsible for the recruitment, migration, and expansion of endothelial cells, with this angiogenesis tumor model being characteristic of RCC. Different strategies have been developed for almost a decade to block the VEGF pathway in this setting. Four different compounds were approved for metastatic RCC (mRCC) in the past 6 years: bevacizumab, sunitinib, sorafenib, and pazopanib. Axitinib and tivozanib are also promising compounds under evaluation. The revolution in the management and prognosis of patients with mRCC is ongoing.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据